UBS Group
WINT

UBS Group’s Windtree Therapeutics WINT Stock Holding History

UBS Group’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22
Closed -$11 – 10995
2025
Q2 		$11 Sell
22
-28,743
-100% -$25.5K ﹤0.01% 10150
2025
Q1 		$36.2K Buy
28,765
+27,573
+2,313% +$170K ﹤0.01% 7823
2024
Q4 		$20.8K Buy
1,192
+1,184
+14,800% +$37.6K ﹤0.01% 7846
2024
Q3 		$925 Buy
+8
New +$2.42K ﹤0.01% 8770
2024
Q2 		– Hold
0
– – – 9362
2024
Q1 		– Sell
-1
Closed -$382 – 9168
2023
Q4 		$366 Sell
1
-6
-86% -$5.29K ﹤0.01% 8705
2023
Q3 		$5.61K Buy
+7
New +$7.76K ﹤0.01% 7357
2023
Q2 		– Hold
0
– – – 8730
2023
Q1 		– Hold
0
– – – 8646
2022
Q4 		– Hold
0
– – – 10458
2022
Q3 		– Sell
-1
Closed -$17.9K – 10991
2022
Q2 		$14K Buy
+1
New +$29.5K ﹤0.01% 7431
2022
Q1 		– Hold
0
– – – 9330
2021
Q4 		– Hold
0
– – – 9171
2021
Q3 		– Hold
0
– – – 8848
2021
Q2 		– Hold
0
– – – 7405
2021
Q1 		– Hold
0
– – – 8537
2020
Q4 		– Hold
0
– – – 8123
2020
Q3 		– Hold
0
– – – 6785
2020
Q2 		– Hold
0
– – – 6409

UBS Group's WINT Position: Q3 2025 in Review

UBS Group sold out of Windtree Therapeutics (WINT) in Q3 2025, closing a stake of 22 shares — an estimated $11 sold.

UBS Group first reported a position in WINT in Q2 2022 and held it in 7 quarters. The position peaked at $36.2K in Q1 2025. 0 funds tracked by Wall St. Rank hold WINT as of Q3 2025.

  • UBS Group reported no remaining Windtree Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 22 Windtree Therapeutics shares in Q3 2025, an estimated $11.
  • UBS Group first reported a position in Windtree Therapeutics in Q2 2022 and held it in 7 quarters.
  • UBS Group's Windtree Therapeutics position peaked at $36.2K in Q1 2025.
  • 0 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.